Small RNAs/Functional Genomics
Support and Educational Content

Guaranteed knockdown of RNA in loss-of-function studies

TriFECTa® RNAi Kits provide potent target DsiRNAs and controls

The RNA interference (RNAi) pathway is a conserved, gene-regulation mechanism found in most eukaryotes that normally influences development and protects the genome from viruses and transposable elements. However, the RNAi pathway can be coopted for therapeutic and research use. After extensive studies to find effective delivery methods, potential RNAi therapies are in clinical trials (e.g., for blood disorders, some cancers, and liver diseases). RNAi also has become the experimental tool of choice for studying the effects of gene knockdown, especially when targeting RNA in the cytoplasm. In mammalian systems, small interfering RNAs (siRNAs) are typically transfected into cells or injected into animals. The siRNA enters the RNAi pathway through incorporation into the RNA-induced silencing complex (RISC), which also includes Dicer, TRBP, and Argonaut 2 proteins [1, for overview or RNAi].

Why use DsiRNAs?

We recommend transfection or electroporation of Dicer-substrate siRNA (DsiRNA) to obtain sustained RNA knockdown in cultured cells. These 27mer duplex DsiRNAs are more potent than traditional 21mer siRNAs [2,3] and can be used at low levels (typically 1–10 nmol) to minimize off-target effects. Predesigned DsiRNAs targeting human, mouse, and rat transcriptomes, are selected using a rational design algorithm that integrates 21mer siRNA design rules and 27mer-specific criteria. Additionally, analysis is performed to ensure that the chosen sites do not target alternatively spliced exons and do not include known single-nucleotide polymorphisms (SNPs). Sequences are also screened to minimize the potential for cross-hybridization and off-target effects (Smith-Waterman analysis).

A cost-effective kit for Predesigned DsiRNA and controls

Whether you are new to RNAi or an experienced user, the TriFECTa RNAi Kit for human, mouse, or rat targets is a convenient, economical option for obtaining Predesigned DsiRNAs and important control DsiRNAs necessary for successful experiments. (Note: if you are studying a species other than human, mouse, or rat, use our Custom DsiRNAs design and ordering tool to choose your DsiRNAs.)

The TriFECTa Kits contain the following:

  • 3 predesigned 27mer RNA duplexes (Predesigned DsiRNAs, 2 nmol each) that are specific for a single target gene. DsiRNAs are provided in individual tubes and can be used singly or pooled, if desired.

  • 3 control DsiRNAs that can be used to optimize your RNAi experimental system before beginning new target studies:

    • Fluorescent dye–labeled DsiRNA (Tye 563 Transfection Control DsiRNA, 1 nmol) can be used to easily monitor transfection of cultured cells (Figure 1A)

    • Positive control DsiRNA (HPRT-S1 Positive Control DsiRNA, 1 nmol) targets a site in the hypoxanthine phosphoribosyntransferase (HPRT) 1 gene that is common between human, mouse, and rat (Figure 1B)

    • Universal negative control DsiRNA (Negative Control DsiRNA, 1 nmol) does not target any sequence in the human, mouse, and rat transcriptomes

  • Nuclease-Free Duplex Buffer (2 mL tube) is included in each TriFECTa Kit. DsiRNAs are provided as RNA duplexes, delivered dry in tubes. Use Nuclease-Free Duplex Buffer to resuspend your DsiRNAs.

High transfection efficiency of DsiRNA into HeLa cells

A. High transfection efficiency of DsiRNA into HeLa cells.

mRNA knockdown measured by RT-qPCR using low levels of DsiRNA

B. mRNA knockdown measured by RT-qPCR using low levels of DsiRNA.

Figure 1. Visualization of transfection efficiency and mRNA knockdown using DsiRNA Controls. (A) Overlay of fluorescence and phase-contrast images is shown. HeLa cells were transfected at a final concentration of 10 nM with the TYE™ 563 Transfection Control DsiRNA using X-tremeGENE® transfection reagent (Roche). Cells were imaged 24 hours post transfection. (B) ) HeLa cells were plated at a density of 2 x 104 cells/well in a 24 well plate. 24 hours later, the cells were transfected with HPRT-S1 Positive Control DsiRNA or negative control DsiRNA using Oligofectamine™ transfection reagent. 24 hours post transfection, RNA was isolated (SV96 Total RNA Isolation Kit, Promega), and HPRT levels were measured by RT-qPCR using an ABI 7000 real-time PCR machine (Thermo Fisher Scientific). Relative expression was normalized to RPLP0 internal control mRNA using the negative control as baseline (100%).

TriFECTa guarantee

Use the Predesigned DsiRNA ordering tool to select the DsiRNAs that will be included in your TriFECTa kit. We guarantee that at least 2 of the 3 Predesigned DsiRNAs in the TriFECTa Kit will result in at least 70% knockdown of the target mRNA when:

  1. DsiRNA is used at 10 nM and assayed by quantitative RT-PCR,

  2. The fluorescent transfection control experiments indicate that >90% of the cells have been transfected, and

  3. The HPRT positive control DsiRNA works with the expected efficiency.

Visit for more information about DsiRNA and DsiRNA controls.


  1. Sabel J (2011) RNAi and DsiRNA: Pathway, mechanism, and design. [Online] Coralville, Integrated DNA Technologies. Available at [Accessed 7 Jul, 2016].

  2. Kim DH, Behlke MA, et al. (2005) Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol, 23(2):222–226.

  3. Rose S, Behlke MD (2013) Synthetic Dicer-substrate siRNAs as triggers of RNA interference. In: Howard KA (editor) RNA Interference from Biology to Therapeutics: Advances in Delivery Science and Technology: Springer US. p 31–56.

  4. Rose SD, Collingwood MA, Behlke MA (2006) Application note: Optimizing knockdown of gene expression using the TriFECTa® Dicer-substrate RNAi reagent system. Nat Methods 3 DOI:10.1038/NMETH919.

Product focus—RNAi reagents

Visit for more information about the following products:

  • Predesigned and Custom DsiRNA—Dicer-substrate siRNAs (DsiRNAs) are chemically synthesized 27mer duplex RNAs that deliver increased potency in RNAi experiments compared to traditional 21mer siRNAs. There are over 322,000 Predesigned DsiRNAs that cover the complete transcriptomes of humans, mice, or rats. Alternatively, use our design algorithm to generate Custom DsiRNAs that target any sequence.

  • Control DsiRNAs—Select from a wide range of positive and negative controls, whether you are optimizing transfection conditions or monitoring your experiments.

  • TriFECTa® RNAi Kit—Conveniently order 3 Predesigned DsiRNAs (to the same target), controls, buffer, and water in a single kit. See for details about our guarantee.

Additional resources

DECODED newsletter articles:

RNAi and DsiRNA: Pathway, mechanism, and design—If you are new to RNA interference, this article provides a helpful overview of the endogenous pathway and how this mechanism can be used in loss-of-function experiments.


Selected DsiRNA citations—View a list of peer-reviewed publications describing how your colleagues have successfully used IDT siRNA products and design tools in their research.


Planning and executing in vitro siRNA experiments—A review of 5 main steps leading to successful siRNA experiments performed in vitro.

Planning and executing in vivo siRNA experiments—A review of 5 main steps leading to successful siRNA experiments performed in vivo.

In vivo RNAi—Considerations and examples—An overview of important considerations when conducting in vivo siRNA experiments followed by an example of an application from a collaboration between scientists from the Université de Sherbrooke (Québec, Canada) and IDT.

Author: Maureen Young, PhD, is a senior scientific writer at IDT.

© 2016 Integrated DNA Technologies. All rights reserved. Trademarks contained herein are the property of Integrated DNA Technologies, Inc. or their respective owners. For specific trademark and licensing information, see

siRNAs with increased potency

Use IDT DsiRNAs to engage the Dicer-processing/RISC-loading mechanisms and get increased silencing potency over traditional siRNAs.

Learn more ≫

Related Articles

RNAi and DsiRNA: Pathway, Mechanism, and Design

An overview of the RNA interference (RNAi) pathway, its applications, and design considerations for gene silencing experiments.

Read more ≫

Using Antisense Technologies to Modulate Noncoding RNA Function

Useful modifications and design considerations for effective antisense oligonucleotides.

Read more ≫

Small RNA Therapies for Cystic Fibrosis

DsiRNAs are used to develop a protocol for efficient small RNA delivery into airway epithelia to study of miRNA regulation of airway fluid and electrolyte transport.

Read more ≫

Using DsiRNA to Map Pain Pathways in the CNS

Canadian laboratory targets pain receptors for expression knock out via in vivo delivery of DsiRNA 27mer duplex RNAs into the mouse CNS.

Read more ≫

The Future of RNAi and Aptamer Technologies—An Interview with John Rossi

An interview with Dr John Rossi, whose research focuses on the biology and applications of eukaryotic small RNAs and, in particular, their therapeutic use in HIV/AIDS and cancer.

Read more ≫